Poor survival outcomes in HER2 positive breast cancer patients with low grade, node negative tumours

Tovey, S.M., Brown, S.B., Doughty, J.C., Mallon, E.A., Cooke, T.G. and Edwards, J. (2009) Poor survival outcomes in HER2 positive breast cancer patients with low grade, node negative tumours. British Journal of Cancer, 100(5), pp. 680-683. (doi: 10.1038/sj.bjc.6604940)

[img] Text
7744.pdf

93kB

Publisher's URL: http://dx.doi.org/10.1038/sj.bjc.6604940

Abstract

We present a retrospective analysis on a cohort of low-grade, node-negative patients showing that human epidermal growth factor receptor 2 (HER2) status significantly affects the survival in this otherwise very good prognostic group. Our results provide support for the use of adjuvant trastuzumab in patients who are typically classified as having very good prognosis, not routinely offered standard chemotherapy, and who as such do not fit current UK prescribing guidelines for trastuzumab.

Item Type:Articles
Keywords:HER2, breast cancer, trastuzumab
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Mallon, Dr Elizabeth and Cooke, Prof Timothy and Edwards, Professor Joanne and Tovey, Ms Sian
Authors: Tovey, S.M., Brown, S.B., Doughty, J.C., Mallon, E.A., Cooke, T.G., and Edwards, J.
Subjects:R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
College/School:College of Medical Veterinary and Life Sciences > Institute of Cancer Sciences
Journal Name:British Journal of Cancer
Publisher:Nature Publishing Group
ISSN:0007-0920
ISSN (Online):1532-1827
Published Online:17 February 2009
Copyright Holders:Copyright © 2009 Nature Publishing Group
First Published:First published in British Journal of Cancer 100(5):680-683
Publisher Policy:Reproduced in accordance with the copyright policy of the publisher.

University Staff: Request a correction | Enlighten Editors: Update this record